

## Correction

**Correction: Impact of Tumor HER2/ERBB2 Expression Level on HER2-Targeted Liposomal Doxorubicin-Mediated Drug Delivery: Multiple Low-Affinity Interactions Lead to a Threshold Effect**

In this article (Mol Cancer Ther 2013;12:1816–28), which appeared in the September 2013 issue of *Molecular Cancer Therapeutics* (1), the authors regret that the article title was incorrect.

The authors forgot to mention the company code of HER2-targeted liposomal doxorubicin (MM-302) for reference. The company code is important for other investigators to link this work with other ongoing clinical trials that are using MM-302. The publisher recommended that correcting the title was the most appropriate means for making this link. The correct title is given below.

"Impact of Tumor HER2/ERBB2 Expression Level on HER2-Targeted Liposomal Doxorubicin (MM-302)-Mediated Drug Delivery: Multiple Low-Affinity Interactions Lead to a Threshold Effect".

**Reference**

1. Hendriks BS, Klinz SG, Reynolds JG, Espelin CW, Gaddy DF, Wickham TJ. Impact of tumor HER2/ERBB2 expression level on HER2-targeted liposomal doxorubicin-mediated drug delivery: multiple low-affinity interactions lead to a threshold effect. Mol Cancer Ther 2013;12:1816–28.

Published online November 12, 2013.

doi: 10.1158/1535-7163.MCT-13-0885

©2013 American Association for Cancer Research.

# Molecular Cancer Therapeutics

## Correction: Impact of Tumor HER2/ERBB2 Expression Level on HER2-Targeted Liposomal Doxorubicin-Mediated Drug Delivery: Multiple Low-Affinity Interactions Lead to a Threshold Effect

*Mol Cancer Ther* 2013;12:2962. Published OnlineFirst November 12, 2013.

**Updated version** Access the most recent version of this article at:  
doi:[10.1158/1535-7163.MCT-13-0885](https://doi.org/10.1158/1535-7163.MCT-13-0885)

**Cited articles** This article cites 1 articles, 1 of which you can access for free at:  
<http://mct.aacrjournals.org/content/12/12/2962.full#ref-list-1>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link  
<http://mct.aacrjournals.org/content/12/12/2962>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.